BioStock: Strong first half of 2020 for Scandion Oncology

Ravaged by a pandemic, the first half of 2020 has not been a walk in the park for most companies. However, when looking at the year so far for Danish biotech company Scandion Oncology, the obstacles put in place by mother nature do not seem to have greatly affected the company, which has been able to reach several important milestones within its drug development. BioStock spoke to Scandion Oncology’s CEO Nils Brünner for a review of the year so far and what to look forward to in the months ahead.

Read the full interview with Nils Brünner, CEO of Scandion Oncology, at biostock.se

https://www.biostock.se/en/strong-first-half-of-2020-for-scandion-oncology/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se